June 25, 2012

HELIX BIOPHARMA CORP. ANNOUNCES SELECTION OF CEO; PLANS TO VOLUNTARILY DELIST FROM NYSE MKT (PDF)

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, NYSE MKT, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that its Board of Directors has approved the selection of Robert Verhagen as Chief Executive Officer. Mr Verhagen is currently a Director for Helix, he is a graduate of the University of Alberta with a Bsc and MBA and has extensive experience in the bio-tech industry. “I am pleased with the selection of Rob from our CEO search. Rob has already contributed significantly to Helix as a Director” said William White, Chairman and Interim CEO of Helix. “I look forward to his leadership of the company taking us forward”. “I have worked with Rob now as a Director and I have been impressed with his knowledge and experience in the industry and his work on the Board to focus Helix on our critical programs” said Marek Orlowski, Director, “I look forward to his leadership of the company to deliver results.” Mr. Verhagen is pleased with the opportunity to make Helix all it can be and said, “As a Board Member, I have seen the great potential of Helix and its programs. As CEO, I look forward to taking the responsibility in converting this potential into real value for all shareholders.”